Morgan Stanley raised the firm’s price target on NeuroPace (NPCE) to $8 from $6 and keeps an Equal Weight rating on the shares following “a strong quarter.” The multiple the firm is applying to its 2024 revenue estimate “strikes a balance” between slower growth neuromodulation peers such as Nevro (NVRO) and LivaNova (LIVN) and higher-growth peers like Axonics (AXNX) as NeuroPace’s growth profile has improved, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NPCE:
- NeuroPace initiated with an Overweight at Cantor Fitzgerald
- NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
